Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CmML, ALL, MDS, and B Cell Malignancies

NCT00672152 is registered in ClinicalTrials.gov with Michael Morse, MD as lead sponsor.

NCT NCT00672152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00672152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CmML, ALL, MDS, and B Cell Malignancies
Lead sponsor
Michael Morse, MD
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2007
Completion date
October 31, 2013
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (all), acute myelogenous leukemia (aml), b cell malignancies, chronic myelogenous leukemia (cml), myelodysplastic syndrome (mds)